Last week, on Wednesday, May 8, AcelRx (NASDAQ: ACRX) reported its financial results from the first quarter of 2019. Though there has not been a huge amount of news to report since the company's last business update in March, it nevertheless appears that AcelRx is moving steadily along with its planned approach to commercialization of Dsuvia.
AcelRx Stock Price (05/07-05/14)
Although AcelRx's stock price dropped over 10% (circled above in blue) after the company's earnings announcement, likely due to Dsuvia's small revenue figure, this initial reaction seems overstated to me. At this